Mechanical Engineering - Apr 20 World’s largest electric truck in
Life Sciences - Apr 20 EPFL part of international effort to create Human Cell Atlas
Medicine - Apr 20 How Do People Die in Switzerland Today?
Medicine - Apr 19 Novartis delivered a strong first quarter and acted to become a more focused medicines company
Medicine - Apr 19 Novartis appoints John Tsai Head of Global Drug Development and Chief Medical Officer
Physics - Apr 18 Art from the lab: the beauty of science
Computer Science - Apr 18 A little fold-up joystick brings haptics to portable devices
Medicine - Apr 18 Sandoz signs agreement with Pear Therapeutics to develop and commercialize prescription digital therapeutics for patients with substance use disorder and opioid use disorders

New Novartis analyses at AAN show siponimod’s efficacy on disability and cognition in secondary progressive MS patients

Medicine Apr 20

Analyses of the EXPAND study showed that siponimod (BAF312) reduced the risk of disability progression largely disassociated from relapses in patients with secondary progressive multiple sclerosis (SPMS) - In EXPAND, siponimod also had a meaningful benefit on patients' cognitive processing speed - Findings add to clinical evidence for siponi

Social Sciences Apr 19

When our view of the world is distorted by algorithms

Algorithms are used to personalize our newsfeed on social media. But the risk is that the points of view we are presented with become increasingly limited and extreme.

Astronomy Apr 17